Summary
This 10-K filing from Boston Scientific Corp (BSX) for the period ending December 30, 1996, and filed on March 31, 1997, represents a snapshot of the company's financial and operational standing at a critical juncture in its history. As a medical device company, BSX was likely focused on growth through innovation and market expansion during this era. Investors would be interested in the company's revenue streams, profitability, product pipeline, and any significant strategic developments, such as acquisitions or new product launches that would have shaped its competitive position.
Key Highlights
- 1The filing covers the fiscal year ending December 30, 1996, providing historical financial data for investors.
- 2Boston Scientific Corporation (BSX) is the subject of this annual report.
- 3The filing date of March 31, 1997, indicates that the report reflects the company's performance and status as of the end of 1996.
- 4Investors can use this document to assess the company's financial health, operational performance, and strategic direction in the late 1990s.
- 5Key areas for investors to scrutinize would include revenue growth, product lines, research and development investments, and competitive landscape.
- 6This 10-K serves as a primary source for understanding BSX's business operations and financial position prior to significant market changes or company expansions.
Frequently Asked Questions
While the provided text is a directory listing and does not contain the full 10-K content, historical context indicates that Boston Scientific Corporation is a global medical technology leader. This filing would detail their business in areas such as medical devices for minimally invasive procedures across various specialties like cardiology, endoscopy, and urology.
An investor can expect to find the company's audited financial statements, including the balance sheet, income statement, and cash flow statement for the fiscal year ending December 30, 1996. This would also include detailed notes to the financial statements, management's discussion and analysis of financial condition and results of operations, and information on significant accounting policies.
The provided directory listing does not contain the full text of the 10-K. However, a standard 10-K filing includes a 'Risk Factors' section where management discloses potential risks that could affect the company's future performance, such as regulatory changes, competition, product liability, and market acceptance. It would also contain forward-looking statements subject to cautionary disclaimers.
This filing provides a baseline for understanding Boston Scientific's financial and operational status in the late 1990s. By examining its revenue sources, profitability, investment in R&D, and strategic priorities from this period, investors can analyze the company's growth trajectory, its ability to adapt to market changes, and the effectiveness of its long-term strategy over the subsequent decades.